{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:12:07Z","timestamp":1783120327905,"version":"3.54.6"},"reference-count":30,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1517\/13543784.2011.617740","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T06:06:18Z","timestamp":1318313178000},"page":"1565-1574","source":"Crossref","is-referenced-by-count":36,"title":["Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma"],"prefix":"10.1517","volume":"20","author":[{"given":"Pamela N","family":"Munster","sequence":"first","affiliation":[{"name":"Department of Medicine","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil I","family":"Daud","sequence":"additional","affiliation":[{"name":"Department of Medicine","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"issue":"3","key":"e_1_3_1_2_1","first-page":"641","article-title":"Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins","volume":"8","author":"Garcia-Carbonero R","year":"2002","unstructured":"Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8(3):641-61","journal-title":"Clin Cancer Res"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2010.04.012"},{"issue":"8","key":"e_1_3_1_4_1","first-page":"1127","article-title":"Pharmacology of antitumor agents from higher plants","volume":"20","author":"Sieber SM","year":"1976","unstructured":"Sieber SM, Mead JA, Adamson RH. Pharmacology of antitumor agents from higher plants. Cancer Treat Rep 1976;20(8):1127-39","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"e_1_3_1_5_1","first-page":"515","article-title":"Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies","volume":"56","author":"Muggia FM","year":"1972","unstructured":"Muggia FM, Creaven PJ, Hansen HH, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56(4):515-21","journal-title":"Cancer Chemother Rep"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.10.016"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb07035.x"},{"issue":"17","key":"e_1_3_1_9_1","first-page":"3782","article-title":"Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I","volume":"58","author":"Yao S","year":"1998","unstructured":"Yao S, Murali D, Seetharamulu P, Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res 1998;58(17):3782-6","journal-title":"Cancer Res"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10434"},{"issue":"4","key":"e_1_3_1_11_1","first-page":"935","article-title":"Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918","volume":"7","author":"Maliepaard M","year":"2001","unstructured":"Maliepaard M, van Gastelen MA, Tohgo A, Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7(4):935-41","journal-title":"Clin Cancer Res"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0765-6"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000274"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050120"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_3_1_16_1","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [Internet]","author":"Chapman PB","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [Internet]. N Engl J Med 2011;Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21639808 [[Cited 26 June 2011]","journal-title":"N Engl J Med"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.2741\/1775"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3529"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.2174\/157489208784638767"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.10.1583"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMR.S6073"},{"key":"e_1_3_1_24_1","unstructured":"Phase I Trial of Karenitecin (KT) Administered Intravenously Daily for Five Consecutive Days in Patients with Advanced Solid Tumors Using Accelerated Dose Titration. - ASCO [Internet].. [date unknown];[cited 15:50:21] Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=200862"},{"key":"e_1_3_1_25_1","unstructured":"Phase I Trial of Karenitecin (KT) Administered Intravenously Daily for Five Consecutive Days in Patients with Advanced Solid Tumors Using Accelerated Dose Titration. - ASCO [Internet]. [date unknown];[cited 15:50:22] Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=200862"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1722"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.6165"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-030"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1931"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01053.x"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.11.019"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2011.617740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:02:35Z","timestamp":1772712155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2011.617740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1517\/13543784.2011.617740"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2011.617740","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]}}}